CONTEXT: Decreased vitamin B12 concentration does not usually result in clinical or hematological abnormalities. Subacute combined spinal cord degeneration and pancytopenia are two serious and rarely displayed consequences that appear in severe deficits. CASE REPORT: We present the case of a patient with subacute combined spinal cord degeneration and pancytopenia secondary to severe and sustained vitamin B12 deficiency. Such cases are rare nowadays and have potentially fatal consequences.
INTRODUCTION
Low serum vitamin B12 levels are common, especially in older people. Vitamin B12 is obtained through animal products consumed in the diet. Vitamin B12 deficiency is usually a response to insufficient intake or gastrointestinal disorders. Because of the low requirements in humans (2.4 mg/day), clinical or subclinical deficit may be delayed. Vitamin B12 deficiency can lead to blood disorders, nervous system disorders or neuropsychiatric conditions. However, the clinical picture does not always accompany the analytical variations. 1 Correction of the deficit is important, especially in severe cases, and neurological sequelae may be irreversible if treatment is not started in good time.
CASE REPORT
We present the case of a 59-year-old patient without allergies or toxic habits, who was a welder by profession, with a history of hypertension and dyspepsia. His diet was varied.
His treatment had been omeprazole, plantago ovata and aspirin for years. He started to experience tingling in both arms one year before the time of this report, and it went on gradually increasing. Six months later, he presented difficulty in walking, feelings of instability and decreased strength in all four limbs, especially the lower limbs. He had been losing the flavor of foods and, in the last month, he presented severe fatigue and rapidly progressive cognitive impairment with memory problems, with episodes of agitation, confusion and incoherent speech. Over the days before going to the hospital, he presented total inability to move the lower extremities and a significant decrease in upper-limb strength, with numbness in both the arms and the legs. vitamin B12 test was requested, and the concentration found was 30 pg/ml (157-1050), while the folate concentration was 9.1 ng/ml (2.76-18.2). Thyroid stimulating hormone and tyrosine T4 concentrations were normal.
Vitamin B12 treatment was started intramuscularly at a dose of 1,000 mcg/day, and with oral administration of B12 complex (0.5 mg) + B6 (250 mg) + B1 (250 mg) twice a day. Gastroscopy with biopsy showed a sliding hiatal hernia, chronic superficial gastritis and severe atrophy with intestinal metaplasia in the antral mucosa. The remaining malabsorption, serological, radiological and immunological evaluations were negative or normal.
After several days of treatment, bone marrow aspiration showed red and white cell hyperplasia with significant megaloblastosis, consistent with vitamin B12 deficiency in the patient, in response to the treatment phase, without other dysplastic signs. Figure 2 shows the evolution of different parameters after starting the treatment with vitamin B12.
Within the first week, the patient's cognitive status was fully restored to normal and the vitamin B12 dose was changed to The traditional treatment for vitamin B12 deficiency consists of intramuscular doses of 1,000 mcg/day for a week, then 1,000 mcg/week for a month and, subsequently, 1,000 mcg/month for life. This avoids involvement of the intrinsic factor produced by parietal cells and its absorption in the terminal ileum. However, it is known that 1% of passively ingested vitamin B12 is absorbed without participation by the intrinsic factor, thus enabling oral treatment with high doses and hematological and neurological response rates that are similar over the short-term, while lowering the cost and being better tolerated. 5, 6 The hematological parameters in our case improved rapidly after treatment was started.
The clinical response is inversely proportional to the magnitude and duration of the disease. 7 Recovery may be complete if symptoms have only been present for a few weeks before the start of treatment. If the interval has been longer, the best that can be hoped for is containment of the symptoms. 8 We made a search for similar cases in different databases (Pubmed, Lilacs, Embase and Scirus) using the terms: "Subacute combined spinal cord degeneration" AND "pancytopenia" AND "vitamin B12 deficiency". The result was only three items in Pubmed ( Table 1 ).
Figure 2.
Evolution of hematological parameters after start of treatment with vitamin B12. All patients with vitamin B12 deficiency should be investigated to determine its cause and wheter it might be reversible. In all cases, replacement therapy should be administered.
Although oral and parenteral administration appear to be equally effective in patients with severe neurological symptoms, it is preferable to begin the treatment intramuscularly to ensure compliance.
